Predictive Technology Group, Inc. engages in the development and commercialization of discoveries and technologies involved in novel molecular diagnostic and pharmaceutical therapeutic and human cells, tissues, and human cellular and tissue-based products. The company is headquartered in Salt Lake City, Utah and currently employs 62 full-time employees. The company went IPO on 2007-07-11. The firm operates through two segments: Human Cell and Tissues Products (HCT/Ps) and diagnostics and therapeutics. The HCT/P segment offers minimally manipulated tissue products intended for homologous use, prepared utilizing extraction methods that reduce the loss of important scaffolding, growth factors and cytokines. The firm's Diagnostics and Therapeutics segment uses data analytics for disease identification and subsequent therapeutic intervention through novel gene-based diagnostics, and companion therapeutics. The company offers genetic tests through a number of Advanced Reproductive Technologies (ART) clinics.The Company’s tests include ARTguide and FertilityDX. The RTguide test is a genetic test for women experiencing infertility and other genetic condition.

Industry: Pharmaceutical Preparations Peers: GENEREX BIOTECHNOLOGY CORP Rebus Holdings, Inc.